Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
May-2015 Volume 9 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
May-2015 Volume 9 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Review

Research into europium complexes as magnetic resonance imaging contrast agents (Review)

  • Authors:
    • Guocan Han
    • Yangwei Deng
    • Jihong Sun
    • Jun Ling
    • Zhiquan Shen
  • View Affiliations / Copyright

    Affiliations: Department of Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China, Ministry of Education Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, Zhejiang 310027, P.R. China
  • Pages: 1561-1566
    |
    Published online on: February 17, 2015
       https://doi.org/10.3892/etm.2015.2297
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Europium (Eu) is a paramagnetic lanthanide element that possesses an outstanding luminescent property. Eu complexes are ideal fluorescence imaging (FI) agents. Eu2+ has satisfactory relaxivity and optical properties, and can realize magnetic resonance (MRI)‑FI dual imaging applications when used with appropriate cryptands that render it oxidatively stable. By contrast, based on the chemical exchange saturation transfer (CEST) mechanism, Eu3+ complexes can provide enhanced MRI sensitivity when used with optimal cryptands, incorporated into polymeric CEST agents or blended with Gd3+. Eu complexes are promising in MRI‑FI dual imaging applications and have a bright future.

Introduction

Magnetic resonance imaging (MRI) is a useful medical imaging technique that utilizes the properties of nuclear magnetic resonance (NMR) to image the nuclei of atoms inside the body in detail and depth (1,2). With high resolution and good safety, MRI is widely used as an efficient information source in medical diagnosis of the whole body. Fluorescence imaging (FI) provides better sensitivity than MRI, but cannot show tissues at different levels. The combination of MRI and FI, as a dual imaging application, should provide a balance between iconography and histology. In addition, diagnosis and treatment are likely to be more accurate and sensitive with an approach where tumors are positioned with MRI and completely removed under the guidance of FI.

The ability of contrast agents to alter the relaxivity of the protons of water molecules that are coordinated to tissue is the key of MRI (1). The trivalent gadolinium ion (Gd3+) has seven unpaired electrons in its outer electron shell, which makes it highly paramagnetic with a short spin-lattice relaxation time (longitudinal relaxation time, T1), and complexes of Gd3+ have been widely used as MRI contrast agents (3). Gd3+ has a similar size to Ca2+ and so the former tends to interfere in the metabolism of Ca2+ in the human body. Therefore, ligands are necessary to reduce the toxicity. Functional groups on the ligands can also be designed to bond with nanoparticles (NPs), in order to extend the rotational correlation time and enhance relaxivity. Ligands that are frequently used include diethylene triamine pentacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and their derivatives (Fig. 1) (3,4).

Figure 1.

Frequently used ligands, diethylene triamine pentacetic acid (DTPA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).

Europium (Eu) is also lanthanide element, which is adjacent to gadolinium in the periodic table, and the application of its ions in MRI has also been the object of attention. Eu3+ has six unpaired electrons in the outer electron shell, which is indicative of good paramagnetism. It is photoluminescent, can emit strong fluorescence (585–630 nm, red) with a long life-time and is barely toxic. If the MRI and FI functions of complexed Eu are both achieved, and the complexes possess sensitivity and accuracy, a series of promising applications are predicted. Xu et al presented a variety of lanthanide oxide (Ln2O3) NPs and studied their water proton relaxivities (5). The authors coated Ln2O3 with D-glucuronic acid to prepare ultrasmall NPs (with diameters of ∼2 nm), and measured their longitudinal relaxivity (r1) and transverse relaxivity (spin-spin relaxivity; r2). The results are listed in Table I (6), and show that the D-glucuronic acid-coated ultrasmall Eu2O3 NPs are not outstanding in r1 or r2. This may be attributed to the spin relaxation time of Eu3+ being too short to alter the relaxivity of protons. To achieve MRI-FI dual imaging, the optimal method is to blend Eu complexes with routine MRI contrast agents, for example, Gd3+ complexes (5,7) and Fe3O4 (8,9). Pinho et al studied the dual imaging capabilities of lanthanide-DTPA-grafted silica NPs, in which Eu3+ and Gd3+ complexes were blended together [SiO2@3-aminopropyl-triethoxysilane (APS)/DTPA:Gd:Eu] (7). The results revealed that the existence of Gd3+ did not disturb the photoluminescence of Eu3+, while the addition of Eu3+ enhanced the relaxivity of Gd3+.

Table I.

Average particle diameter (davg), r1, and r2 of D-glucuronic acid-coated ultrasmall Ln2O3 nanoparticles and the M values of Ln(III) in ultrasmall Ln2O3 nanoparticles (6).

Table I.

Average particle diameter (davg), r1, and r2 of D-glucuronic acid-coated ultrasmall Ln2O3 nanoparticles and the M values of Ln(III) in ultrasmall Ln2O3 nanoparticles (6).

Ma(µB)

Ln2O3 nanoparticledavg (nm)5K300Kr1b (mM‒1 sec‒1)r2b (mM‒1 sec‒1)
Eu2O32.00.0780.0460.0063.82
Gd2O32.46.420.244.2527.11
Dy2O32.95.190.420.1640.28
Ho2O32.44.660.390.1331.24
Er2O32.94.520.340.0614.74

a Measured with a magnetic field intensity of 5T.

b Measured at 22˚C with a magnetic field intensity of 1.5T. r1, longitudinal relaxivity; r2, transverse relaxivity; Ln, lanthanide; Eu, europium, Gd, gadolinium; Dy, dysprosium; Ho, holmium; Er, erbium; M, magnetization.

However, in order to realize MRI-FI dual imaging with Eu complexes in the absence of highly paramagnetic ions, it is necessary to focus attention on improving the MRI properties of Eu complexes.

Studies of Eu2+ complexes as MRI contrast agents

Eu2+ has seven unpaired electrons in its outer electron shell, as does Gd3+. However, Eu2+ has a larger ion size than Gd3+ and a lower charge, which gives Eu2+ a faster water-exchange rate and guarantees a relatively high relaxivity (10). Eu2+ is also photoluminescent; f→d transitions have been observed in Eu2+, which have longer radiative emission lifetimes than f→f transitions in Eu3+ (11). However, the relaxivity of Eu2+-containing DTPA chelates has been found to be 20% lower than that of Gd3+-DTPA complexes at 20 MHz, which may be attributed to the fast ionic spin relaxation of Eu2+ (12). Not all Eu2+ complexes are restricted by ionic spin relaxation. The relaxivity of Eu2+-DOTA complexes has been shown to reach 4.74 mM−1sec−1 at 20 MHz and 298K, much higher than that of Eu2+-DTPA complexes (13). A fast water-exchange rate of Eu2+ is able to offset the disadvantage in ionic spin relaxation time.

The biggest obstacle in the development of MRI applications of Eu2+ complexes is the oxidative stability of the ion. Eu2+ has a propensity for being oxidized to Eu3+, which possesses low relaxivity and relatively high toxicity. Coordination chemistry principles can be used to oxidatively stabilize Eu2+ without weakening the relaxivity and water-exchange rate. 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (crypt-222; ligand 1 in Fig. 2A) is known to have an appropriate cage size for Eu2+, and the crypt-222 complex [Eu(crypt-222)(H2O)2]2+ is one of the most redox-stable Eu2+ chelates (14). [Eu(crypt-222)]2+ coordinates immediately with two water molecules, and possesses an appropriate water-exchange rate and ionic spin relaxation time. However, [Eu(crypt-222)(H2O)2]2+ is not sufficiently stable for the development of MRI applications in aqueous solution. However, it is potentially useful as a pO2-responsive macromolecular MRI contrast agent (14).

Figure 2.

4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (crypt-222; ligand 1) and its derivatives (ligands 2–6).

To obtain oxidatively stable aqueous Eu2+ complexes, Gamage et al carried out research and development based on the coordination of crypt-222 (15). The goals were: i) to increase the surrounding steric bulk to minimize interactions between Eu2+ and its environment; ii) to reduce the Lewis basicity of crypt-222 to favor Eu2+ over Eu3+; iii) to change the cavity size of the cryptand to match the size of the Eu2+ ion preferentially; and iv) to modify the hard-soft, acid-base (HSAB) properties of crypt-222 to coordinate Eu2+ in preference to Eu3+. The authors presented five ligands (ligands 2–6 in Fig. 2) with crypt-222 as the prototype.

The steric bulk of ligand 2 was increased by the addition of methyl groups. Benzene rings were introduced to decrease the ion-donating ability of the adjacent oxygen atoms of ligands 3–5. The introduction of fluorine in ligand 4 and another benzene ring in ligand 5 modulated the extent of ion withdrawal. The existence of fused benzene moieties decreased the cavity size of the cryptand and provided a cavity size closer to that of Eu2+. In ligand 6, relatively soft sulfur-atom donors were introduced to take the place of oxygen-atom donors, enabling the influence of HSAB properties to be explored. In situ, the authors mixed these ligands with Eu(NO3)3·5H2O in aqueous solution. The mixture was placed in a standard three-electrode cell while the potential at the carbon electrode was held at −0.8 V to achieve metal complexation. Cyclic voltammograms were obtained following metallation for each complex in solution with ferrocene as an internal standard. Anodic peak potentials for each complex were obtained and are listed in Table II.

Table II.

Anodic peak potentials (Epa) of various samples with respect to ferrocene/ferrocenium (Fc/Fc+).

Table II.

Anodic peak potentials (Epa) of various samples with respect to ferrocene/ferrocenium (Fc/Fc+).

SampleEpa vs. Fc/Fc+ (V)SampleEpa vs. Fc/Fc+ (V)
1. Eu(NO3)3−0.701±0.0305. Eu−2−0.169±0.006
2. Eu−1−0.336±0.0166. Eu−4−0.079±0.007
3. Eu−5−0.211±0.0047. hemoglobin−0.070±0.003
4. Eu−3−0.208±0.0098. Eu−6−0.035±0.010

[i] Eu−n (n=1−6) is a complex of europium (Eu2+) with ligand n; ligand 1 is 4,7,13,16,21,24−hexaoxa−1,10−diazabicyclo[8.8.8]hexacosane (crypt−222); ligands 2−6 are crypt−222 derivatives as shown in Fig. 2.

The results revealed that the new ligands all increased the oxidative stability of Eu2+ to a certain degree. There was almost no difference between the Eu complexes of ligands 5 and 3, indicating that the addition of one benzene ring was sufficient for stabilization. The Eu complex of ligand 6 had the highest anodic peak potential, higher than that of Fe2+-hemoglobin, suggesting that it was an efficient ligand to prevent Eu2+ from oxidation. Garcia et al also reported the stability of Eu complexes with ligands 1 and 3 in the presence of Ca2+, Mg2+ and Zn2+ (16), and the study indicated that the Eu2+ complexes remained stable in the presence of Ca2+, Mg2+ and Zn2+ at concentrations 1.87-20-fold higher than biological concentrations. Eu2+ complexes have the potential to realize durable biological oxidative stability, and provide satisfactory magnetic and spectroscopic properties in vivo.

MRI of Eu3+ complexes based on CEST

Chemical exchange saturation transfer (CEST) is a novel mechanism for generating image contrast in MRI (1). Protons on ligands or water molecules coordinated with a metal ion are saturated by a radiofrequency pulse and then exchanged with bulk water molecules, presenting a negative image. Imaging can be made more efficient by the utilization of paramagnetic nuclei. The effects of these agents, referred to as PARACEST agents, can be switched on and off depending on the application of radiofrequency radiation. Theoretically, with an optimal water-exchange rate, chemical shift and relaxation properties, the detection limit of a single PARACEST exchanging species is comparable to that of a single Gd3+-based T1 imaging agent (17). The applications of CEST include the visualization of living tissue structure, the imaging of metabolic processes, the marking of cells and pH measurements (18).

Zhang et al studied the CEST properties of a complex of Eu3+ with a DOTA-tetraamide derivative (ligand 7 in Fig. 3) (19). 1H NMR spectroscopy was used to examine an aqueous solution of the Eu complex of ligand 7 (Fig. 4A). The peak corresponding to complexed water shifted to ∼50 ppm. If protons were exchanged between the complexed water and bulk water following the application of radiofrequency energy, the signal intensities of would change, revealing directly the ratio of saturated protons. The ratio of saturated protons is defined as Ms/M0, where Ms is the water proton signal in the presence of saturation and M0 is the signal under control conditions. CEST curves were drawn based on the aforementioned method (Fig. 4B). Lower MsM0 values indicated higher CEST effects. Magnetization transfer T1-weighted spin-echo images for a phantom were obtained with no saturation (Fig. 5A), saturation at +9,800 Hz (Fig. 5B) and saturation at −9,800 Hz (Fig. 5C). The image at +9,800 Hz was dimmer than the others, demonstrating the weakening effect of CEST on the magnetic resonance signals of protons, and the ability to be switched on and off at will was achieved.

Figure 3.

1,4,7,10-Tetraazacyclododecane tetrakis (ethyl-acetamidoacetate), ligand 7. Et, ethyl.

Figure 4.

(A) 1H nuclear magnetic resonance spectrum and (B) chemical exchange saturation transfer curve of Eu-7 in aqueous solution. Eu-7 is a complex of europium (Eu3+) with 1,4,7,10-tetraazacyclododecane tetrakis(ethyl-acetamidoacetate). Ms/M0, ratio of saturated protons; Ms, water proton signal in the presence of saturation; M0, signal under control conditions; ppm, parts per million.

Figure 5.

Magnetization transfer T1-weighted spin-echo images of a phantom. The outer vial contained deionized water, while inner vial contained 63 mM Eu-7 dissolved in pure water. (A) No saturation, (B) saturation at +9,800 Hz and (C) saturation at −9,800 Hz. Eu-7 is a complex of europium (Eu3+) with 1,4,7,10-tetraazacyclododecane tetrakis(ethyl-acetamidoacetate).

To lower the detection limit of PARACEST agents, Wu et al reported the polymerization of PARACEST agents in order to enhance MRI contrast sensitivity (17). The authors presented two kinds of DOTA ligands with acrylamide substituents to coordinate with Eu3+ (ligands 8 and 9 in Fig. 6), and synthesized polymeric ligands by the respective radical polymerization of ligands 8 and 9 (poly 8 and poly 9 in Fig. 6). The CEST spectra of Eu complexes of ligands 9 and poly 9 were almost identical at equal Eu3+ concentrations (Fig. 7), suggesting that the polymerization had no impact of the exchange of protons. A comparison among the maximum CEST for each concentration of the Eu complexes of ligand 9 and poly 9 with different initiator ratios (Fig. 8) revealed that polymerization efficiently lowered the detection limit.

Figure 6.

1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid derivatives with acrylamide substituents (ligands 8 and 9) and their polymers (poly 8 and poly 9, respectively). Et, ethyl.

Figure 7.

Chemical exchange saturation transfer spectra of Eu-9 (red) and Eu-poly 9 (2%; blue); concentration of Eu3+, 30 mM. Eu-9 is a complex of europium (Eu3+) with an acrylamide-substituted derivative of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (ligand 9), and Eu-poly 9 is a complex of Eu3+ with a polymer of ligand 9. Ms/M0, ratio of saturated protons; Ms, water proton signal in the presence of saturation; M0, signal under control conditions; ppm, parts per million.

Figure 8.

Maximum chemical exchange saturation transfer per concentration of agent [agent] for Eu-9 (▲) and Eu-poly 9 (•, 2%; ▪, 5%; ♦,10%). Eu-9 is a complex of europium (Eu3+) with an acrylamide-substituted derivative of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (ligand 9), and Eu-poly 9 is a complex of Eu3+ with a polymer of ligand 9. Ms/M0, ratio of saturated protons; Ms, water proton signal in the presence of saturation; M0, signal under control conditions.

In another article from these authors, 2-methylacrylic acid (MAA), 2-(acryloylamino)-2-methyl-1-propanesulfonic acid (AMPS) and N-isopropylacrylamide (NIPAM) were respectively used to copolymerize with ligand 9, to form the polymers DMAA, DAMPS and DNIPAM (D: ligand 9), respectively (Fig. 9), in order to investigate the effect of water-exchange rate on the CEST properties of Eu3+ complexes (20).

Figure 9.

Copolymers of an acrylamide-substituted derivative of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (ligand 9) with 2-methylacrylic acid (MAA), 2-(acryloylamino)-2-methyl-1-propanesulfonic acid (AMPS) and N-isopropylacrylamide (NIPAM). Et, ethyl; D, ligand 9.

Unlike Gd3+-based T1 imaging agents that rely on rapid water exchange between metal ion-bound water and bulk solvent, the signals of PARACEST agents become quenched as the bound protons on the agent are not readily saturated at a rapid water-exchange rate; they require moderate-to-slow water exchange rates for optimal performance. From the CEST results of an Eu complex of DMAA at different pH values (Fig. 10), the signals were attenuated as the pH was reduced from 8 to 4. The carboxyl group was stable enough to bond with water at lower pH and water exchange between water and the complexes was promoted. Copolymerization also rendered the complexes responsive to temperature. The water-exchange rate increased as the temperature rose. However, unlike DMAA, which is hydrophilic along the full length of the polymer, the interaction between water and the side groups of DNIPAM was attenuated when the temperature rose, and the side groups tended to aggregate against water, which avoided an unfavorably rapid exchange rate. The aforementioned factors explain why changes in the signals generated by the Eu-DNIPAM complex were more moderate than those generated by Eu-DMAA as the temperature changed. The results of these studies indicate that Eu3+-based CEST agents are promising for use in pH- and temperature-responsive MRI applications.

Figure 10.

Chemical exchange saturation transfer curves of Eu-DMAA at different pH values. Eu-DMAA is a complex of europium (Eu3+) with a copolymer of an acrylamide-substituted derivative of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (ligand 9) and 2-methylacrylic acid (MAA). Ms/M0, ratio of saturated protons; Ms, water proton signal in the presence of saturation; M0, signal under control conditions; ppm, parts per million.

Conclusion and prospects

Eu3+ and Eu2+ possesses six and seven unpaired electrons in the 4f orbital, respectively, which is indicative of paramagnetism. However, the short ionic spin relaxation time of Eu3+ and the propensity of Eu2+ to be oxidized result in the MRI properties of Eu complexes being inferior to those of Gd complexes. The design of ligands and enhancement by CEST are the main approaches at present to compensate for the deficiencies of Eu ions, enhance their properties as MRI contrast agents and eventually realize MRI-FI dual imaging with further efforts.

Acknowledgements

This study was supported by National Basic Research Program of China (973 Program, no. 2014CB744505), National Natural Science Foundation of China (no. 81430040) and Scientific Research Foundation of Health Bureau of Zhejiang Province in China (no. 2014PYA010).

References

1 

Dorweiler JD, Nemykin VN, Ley AN, Pike RD and Berry SM: Structural and NMR characterization of Sm(III), Eu(III) and Yb(III) complexes of an amide based polydentate ligand exhibiting paramagnetic chemical exchange saturation transfer abilities. Inorg Chem. 48:9365–9376. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Wang LY, Chen QY and Wei B: MRI contrast agent for the diagnosis of tumor. Hua Xue Jin Zhan. 22:186–193. 2010.[(In Chinese)].

3 

Liu Y and Zhang N: Gadolinium loaded nanoparticles in theranostic magnetic resonance imaging. Biomaterials. 33:5363–5375. 2012. View Article : Google Scholar : PubMed/NCBI

4 

Lee GH, Chang YM and Kim TJ: Blood-pool and targeting MRI contrast agents: From Gd-chelates to Gd-nanoparticles. Eur J Inorg Chem. 2012:1924–1933. 2012. View Article : Google Scholar

5 

Xu W, Kattel K, Park JY, Chang Y, Kim TJ and Lee GH: Paramagnetic nanoparticle T1 and T2 MRI contrast agents. Phys Chem Chem Phys. 14:12687–12700. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Kattel K, Park JY, Xu W, et al: A facile synthesis, in vitro and in vivo MR studies of D-glucuronic acid-coated ultrasmall Ln2O3 (Ln = Eu, Gd, Dy, Ho and Er) nanoparticles as a new potential MRI contrast agent. ACS Appl Mater Interfaces. 3:3325–3334. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Pinho SL, Faneca H, Geraldes CF, Delville MH, Carlos LD and Rocha J: Lanthanide-DTPA grafted silica nanoparticles as bimodal-imaging contrast agents. Biomaterials. 33:925–935. 2012.PubMed/NCBI

8 

Wang W, Zou M and Chen K: Novel Fe3O4@YPO4: Re (Re = Tb, Eu) multifunctional magnetic-fluorescent hybrid spheres for biomedical applications. Chem Commun (Camb). 46:5100–5102. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Xi P, Cheng K, Sun X, Zeng Z and Sun S: Magnetic Fe3O4 nanoparticles coupled with a fluorescent Eu complex for dual imaging applications. Chem Commun (Camb). 48:2952–2954. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Garcia J and Allen MJ: Developments in the coordination chemistry of europium (II). Eur J Inorg Chem. 2012:4550–4563. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Kim JM, Jeong YK, Sohn Y and Kang JG: Synthesis and photophysical properties of an Eu(II)-complex/PS blend: Role of Ag nanoparticles in surface-enhanced luminescence. Langmuir. 28:9842–9848. 2012. View Article : Google Scholar : PubMed/NCBI

12 

Seibig S, Tóth É and Merbach AE: Unexpected differences in the dynamics and in the nuclear and electronic relaxation properties of the isoelectronic [EuII(DTPA)(H2O)]3- and [GdIII(DTPA) (H2O)]2− complexes (DTPA = diethylenetriaminepentaacetate). J Am Chem Soc. 122:5822–5830. 2000. View Article : Google Scholar

13 

Burai L, Tóth É, Moreau G, Sour A, Scopelliti R and Merbach AE: Novel macrocyclic EuII complexes: Fast water exchange related to an extreme M-Owater distance. Chemistry. 9:1394–1404. 2003. View Article : Google Scholar : PubMed/NCBI

14 

Burai L, Scopelliti R and Tóth É: EuII-cryptate with optimal water exchange and electronic relaxation: A synthon for potential pO2 responsive macromolecular MRI contrast agents. Chem Commun (Camb). 20:2366–2367. 2002. View Article : Google Scholar : PubMed/NCBI

15 

Gamage NDH, Mei YJ, Garcia J and Allen MJ: Oxidatively stable, aqueous europium(II) complexes through steric and electronic manipulation of cryptand coordination chemistry. Angew Chem Int Ed Engl. 49:8923–8925. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Garcia J, Kuda-Wedagedara AN and Allen MJ: Physical properties of Eu2+-containing cryptates as contrast agents for ultra-high field magnetic resonance imaging. Eur J Inorg Chem. 2012:2135–2140. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Wu Y, Zhou Y, Ouari O, et al: Polymeric PARACEST agents for enhancing MRI contrast sensitivity. J Am Chem Soc. 130:13854–13855. 2008. View Article : Google Scholar : PubMed/NCBI

18 

Wu CM and Jin JY: Research progress of CEST agent in MR imaging. Guoji Yixue Fangshexue Zazhi. 32:475–477. 2009.[(In Chinese)].

19 

Zhang S, Winter P, Wu K and Sherry AD: A novel europium(III)-based MRI contrast agent. J Am Chem Soc. 123:1517–1518. 2001. View Article : Google Scholar : PubMed/NCBI

20 

Wu Y, Zhao P, Kiefer GE and Sherry AD: Multifunctional polymeric scaffolds for enhancement of PARACEST contrast sensitivity and performance: Effects of random copolymer variations. Macromolecules. 43:6616–6624. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Han G, Deng Y, Sun J, Ling J and Shen Z: Research into europium complexes as magnetic resonance imaging contrast agents (Review). Exp Ther Med 9: 1561-1566, 2015.
APA
Han, G., Deng, Y., Sun, J., Ling, J., & Shen, Z. (2015). Research into europium complexes as magnetic resonance imaging contrast agents (Review). Experimental and Therapeutic Medicine, 9, 1561-1566. https://doi.org/10.3892/etm.2015.2297
MLA
Han, G., Deng, Y., Sun, J., Ling, J., Shen, Z."Research into europium complexes as magnetic resonance imaging contrast agents (Review)". Experimental and Therapeutic Medicine 9.5 (2015): 1561-1566.
Chicago
Han, G., Deng, Y., Sun, J., Ling, J., Shen, Z."Research into europium complexes as magnetic resonance imaging contrast agents (Review)". Experimental and Therapeutic Medicine 9, no. 5 (2015): 1561-1566. https://doi.org/10.3892/etm.2015.2297
Copy and paste a formatted citation
x
Spandidos Publications style
Han G, Deng Y, Sun J, Ling J and Shen Z: Research into europium complexes as magnetic resonance imaging contrast agents (Review). Exp Ther Med 9: 1561-1566, 2015.
APA
Han, G., Deng, Y., Sun, J., Ling, J., & Shen, Z. (2015). Research into europium complexes as magnetic resonance imaging contrast agents (Review). Experimental and Therapeutic Medicine, 9, 1561-1566. https://doi.org/10.3892/etm.2015.2297
MLA
Han, G., Deng, Y., Sun, J., Ling, J., Shen, Z."Research into europium complexes as magnetic resonance imaging contrast agents (Review)". Experimental and Therapeutic Medicine 9.5 (2015): 1561-1566.
Chicago
Han, G., Deng, Y., Sun, J., Ling, J., Shen, Z."Research into europium complexes as magnetic resonance imaging contrast agents (Review)". Experimental and Therapeutic Medicine 9, no. 5 (2015): 1561-1566. https://doi.org/10.3892/etm.2015.2297
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team